Intervention

CAD106

ClinicalTrials.gov intervention label

Clinical trials6

Recruiting0

Common conditions2

Lead sponsors shown2

Clinical trials

6 shown

Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer PatientsNCT01097096 · 2010-03-01

To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's PatientsNCT01023685 · 2009-12-01

To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's PatientsNCT00956410 · 2009-09-01

Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's PatientsNCT00795418 · 2008-10-01

Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Mild Alzheimer's Patients.NCT00733863 · 2008-07-01

Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)NCT00411580 · 2005-06-01

Common conditions

Alzheimer Disease3 Alzheimer's Disease3

Leading sponsors

Novartis4 Novartis Pharmaceuticals2

Trial status mix

COMPLETED6

Phase mix

PHASE25

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.